Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension

28 Feb 2023

• By Alaric DeArment

Theravance announced its fourth quarter and full year 2022 earnings • Source: Shutterstock

Related Content

Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study

24 Aug 2021

Theravance To Slash Headcount By 75% After Latest Clinical Trial Setback

15 Sep 2021

Related Companies

Theravance Biopharma Inc.

GSK plc

Pfizer Inc.

Johnson & Johnson

Janssen Biotech Inc.

AbbVie Inc.

Additional Topics

Sales & Earnings Commercial Cardiovascular Respiratory BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.